5.67
price down icon3.24%   -0.19
pre-market  プレマーケット:  5.50   -0.17   -3.00%
loading

Aura Biosciences Inc (AURA) 最新ニュース

pulisher
Mar 31, 2025

Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com

Mar 31, 2025
pulisher
Mar 29, 2025

(AURA) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 28, 2025

Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com

Mar 27, 2025
pulisher
Mar 26, 2025

Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology

Mar 26, 2025
pulisher
Mar 26, 2025

Bel-sar shows promising safety, efficacy in NMIBC - Urology Times

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences Reports Progress in Cancer Trials - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports 'Robust' Anti-Tumor Immune Response From Phase 1 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough: New Bladder Cancer Drug Achieves 80% Response Rate in Clinical Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Analysts Set Groupon, Inc. (NASDAQ:GRPN) PT at $17.33 - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Innovative Industrial Properties, Inc. (NYSE:IIPR) Receives $102.00 Average Target Price from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Target Price from Brokerages - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com

Mar 19, 2025
pulisher
Mar 19, 2025

Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN

Mar 16, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 03, 2025

Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences to present new bladder cancer study data - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences to Present Phase 1 Data on Bel-sar and Host Virtual Urologic Oncology Investor Event at 40th Annual EAU Congress - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Will Aura's Bladder Cancer Treatment Change Patient Outcomes? New Data Coming in 2025 - StockTitan

Mar 03, 2025
pulisher
Feb 25, 2025

How to Take Advantage of moves in (AURA) - news.stocktradersdaily.com

Feb 25, 2025
pulisher
Feb 25, 2025

Syndax Announces Participation in March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

How Will Aura Biosciences Address Investors at Two Major Healthcare Conferences Next Month? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer: Key Trend Transfo... - WhaTech

Feb 24, 2025
pulisher
Feb 23, 2025

Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World

Feb 23, 2025
pulisher
Feb 19, 2025

Aura Biosciences CEO sells shares worth $156,795 - Investing.com India

Feb 19, 2025
pulisher
Feb 18, 2025

Aura Biosciences chief medical officer sells $19,638 in stock By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 18, 2025

Aura Biosciences CEO sells shares worth $156,795 By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Aura Biosciences CTO sells shares for $16,670 By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 18, 2025

Aura Biosciences senior VP sells $10,881 in stock to cover taxes - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Aura Biosciences chief medical officer sells $19,638 in stock - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Aura Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 18, 2025
pulisher
Feb 18, 2025

Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs Market 2034: - openPR

Feb 18, 2025
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
大文字化:     |  ボリューム (24 時間):